

Anna Raimbault

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5921575/publications.pdf>

Version: 2024-02-01

15
papers

853
citations

1163117

8
h-index

1125743

13
g-index

15
all docs

15
docs citations

15
times ranked

1972
citing authors

#	ARTICLE	IF	CITATIONS
1	Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy. <i>Leukemia</i> , 2021, 35, 712-723.	7.2	10
2	p53 activation during ribosome biogenesis regulates normal erythroid differentiation. <i>Blood</i> , 2021, 137, 89-102.	1.4	46
3	Identification and genetic characterization of a <i>NUP98-HHEX</i> molecular rearrangement in a pediatric acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 3531-3535.	1.3	1
4	Holding on to the Matutes score while dropping FMC7: new opportunity from standardised approaches in multiparameter flow cytometry. <i>British Journal of Haematology</i> , 2020, 190, e255-e258.	2.5	4
5	Germline DDX41 mutations define a significant entity within adult MDS/AML patients. <i>Blood</i> , 2019, 134, 1441-1444.	1.4	153
6	ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants. <i>Blood Advances</i> , 2019, 3, 2962-2979.	5.2	110
7	CD13 expression in B cell malignancies is a hallmark of plasmacytic differentiation. <i>British Journal of Haematology</i> , 2019, 184, 625-633.	2.5	10
8	Prognostic Impact of Clonal Diversity in Acute Myeloid Leukemia (AML) Treated with Intensive Chemotherapy (IC). <i>Blood</i> , 2019, 134, 2700-2700.	1.4	1
9	A landscape of germ line mutations in a cohort of inherited bone marrow failure patients. <i>Blood</i> , 2018, 131, 717-732.	1.4	240
10	Myeloid Malignancy Variant Curation Expert Panel: An ASH-Sponsored Clingen Expert Panel to Optimize and Validate Acmg/AMP Variant Interpretation Guidelines for Genes Associated with Inherited Myeloid Neoplasms. <i>Blood</i> , 2018, 132, 5849-5849.	1.4	0
11	Clinical and Molecular Characteristics of DDX41-Mutated Patients in a Large Cohort of Sporadic MDS/AML. <i>Blood</i> , 2018, 132, 797-797.	1.4	1
12	Intra-Tumor Heterogeneity in Acute Myeloid Leukemia (AML): Results from a Real Life Cohort. <i>Blood</i> , 2018, 132, 1537-1537.	1.4	0
13	Comprehensive Proteomic Analysis of Human Erythropoiesis. <i>Cell Reports</i> , 2016, 16, 1470-1484.	6.4	183
14	Dysmegakaryopoiesis of FPD/AML pedigrees with constitutional RUNX1 mutations is linked to myosin II deregulated expression. <i>Blood</i> , 2012, 120, 2708-2718.	1.4	93
15	Flow Cytometry Thresholds of Myeloperoxidase Detection to Discriminate Between Acute Lymphoblastic or Myeloblastic Leukemia. <i>Blood</i> , 2012, 120, 1450-1450.	1.4	1